Supernus Pharmaceuticals Q2 2026: Revenue Beat Masked by $54.9M Impairment

Supernus reported Q2 2026 revenue of $219.1 million, coming in 6.6% ahead of the $205.4 million consensus estimate, and the company followed that up by raising its full-year guidance. On those operational metrics alone, the quarter looked solid. But a $54.9 million impairment charge tied to APOKYN wiped out any bottom-line gains, pushing GAAP earnings to a loss of $1.01 per share against an estimate of $0.51 — a result that stood in sharp contrast to the non-GAAP beat the company had delivered in each of the prior several quarters.

The bigger story overshadowing the quarterly numbers is the announced all-stock merger of equals with Indivior. The deal is structured to combine the two companies into a scaled central nervous system platform, with neither side paying a cash premium. For investors, the transaction reframes how to think about Supernus going forward — the near-term earnings trajectory matters less than how the combined entity's pipeline and commercial footprint will stack up against larger CNS-focused peers.

The APOKYN impairment is a one-time accounting charge rather than a cash outflow, so the headline loss per share of $1.01 is somewhat misleading as a gauge of operating health. The quarter before, in Q1 2026, Supernus earned $0.21 per share, itself below the $0.28 estimate, suggesting the underlying business was already navigating some pressure even before the impairment hit. With the Indivior merger now the dominant variable, the next key milestones to watch are regulatory and shareholder approvals for the combination.